0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Invited Commentary | 
David H. Berger, MD, MHCM
JAMA Surg. 2014;149(5):457-458. doi:10.1001/jamasurg.2013.4163.

Original Investigation | 
Ramesh B. Batchu, PhD; Oksana Gruzdyn, BS; Ravindra B. Potti, PhD; et al.
JAMA Surg. 2014;149(5):451-457. doi:10.1001/jamasurg.2013.4113.

Invited Critique | 
Ronan Cahill, MD
JAMA Surg. 2013;148(3):231. doi:10.1001/jamasurg.2013.703.

Invited Critique | 
Steven D. Colquhoun, MD
Arch Surg. 2012;147(11):1061. doi:10.1001/jamasurg.2013.493.

Review Article |  FREE
Kevin P. Charpentier, MD
Arch Surg. 2012;147(11):1053-1061. doi:10.1001/2013.jamasurg.100.

Paper |  FREE
Daniel Vallböhmer, MD; Jeffrey H. Peters, MD; Hidekazu Kuramochi, MD; et al.
Arch Surg. 2006;141(5):476-482. doi:10.1001/archsurg.141.5.476.

Sign in

Purchase Options

• Subscribe to the journal

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Review  | 
Therapeutic Advances and Treatment Options in Metastatic Melanoma
Douglas B. Johnson, MD, MSCI; Jeffrey A. Sosman, MD
JAMA Oncology
Viewpoint  | 
How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy
Michael D. Farwell, MD; Amy S. Clark, MD, MSCE; David A. Mankoff, MD, PhD
JAMA Oncology
From The JAMA Network  | 
Combination Immunotherapy for Melanoma
Howard L. Kaufman, MD
JAMA Oncology
Research Letter  | 
Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias
Stephanie K. Fabbro, MD; Sabrina M. Smith, BS; Jason A. Dubovsky, PhD; et al.